PMC3861562_01
Changes in AFP and DCP levels. The duration of treatment with sorafenib is indicated by the gray bar. The administration of sorafenib resulted in a significant reduction in serum AFP and DCP levels. AFP, alpha-fetoprotein; DCP, des-gamma carboxyprothrombin.
OL-07-01-0050-g00.jpg
PMC3861562_01_OL-07-01-0050-g00.jpg
f1-ol-07-01-0050
A and tumor marker levels were high: alpha-fetoprotein (AFP), 4,773 ng/ml; AFP-L3, 60.5%; and des-gamma carboxyprothrombin (DCP), 17,400 mAU/ml (Fig. 1). Abdominal computed tomography (CT) showed numerous tumors in the bilateral lobes and a PVTT in the right portal branch (Fig. 2).
Dynamic computed tomography (CT) prior to treatment. (A) Arterial phase and (B) equilibrium phase showing several hepatocellular carcinomas (arrows) in the left hepatic lobe and biloma (arrow head) by the segmentectomy in S5 liver surface. (C) Arterial phase showing portal vein tumor thrombus (arrow) in the right portal branch.
OL-07-01-0050-g01.jpg
PMC3861562_01_OL-07-01-0050-g01.jpg
f2-ol-07-01-0050
A and tumor marker levels were high: alpha-fetoprotein (AFP), 4,773 ng/ml; AFP-L3, 60.5%; and des-gamma carboxyprothrombin (DCP), 17,400 mAU/ml (Fig. 1). Abdominal computed tomography (CT) showed numerous tumors in the bilateral lobes and a PVTT in the right portal branch (Fig. 2).